Merck (MRK) Announces Completion of TRA 2˚P-TIMI 50 Clinical
More News related to MRK
- Merck (MRK) Delays ProQuad Vaccine Once Again - DJN
- Merc Announces Election of New Director
- Merc Announces Election of New Director
- Go Red For Women(R) and Jennie Garth Ask Women to Speak Up About Their No. 1 Killer
- PROLOR Biotech Reports Merck Receives Final Marketing Authorization in Europe for Long-Acting CTP-Modified Fertility Treatment ELONVA(R) (FSH-CTP)
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Merck (NYSE: MRK) announced today the completion of patient enrollment in the TRA 2˚P-TIMI 50 clinical trial, a Phase III, randomized, double-blind, placebo-controlled, multinational study of SCH 530348, the company’s investigational antiplatelet protease activated receptor-1 (PAR-1) inhibitor. The study, conducted by the Thrombolysis in Myocardial Infarction (TIMI) Study Group, reached its target of more than 26,000 patients.
The trial will assess the ability of SCH 530348, a thrombin receptor antagonist, or PAR-1 inhibitor, to prevent major cardiovascular events when added to current antiplatelet regimens (aspirin or aspirin + ADP inhibitor) in patients who have previously experienced a heart attack or stroke or who have peripheral arterial disease.
SCH 530348 is also being studied in the treatment of patients with acute coronary syndrome (ACS) in the ongoing Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER) trial, led by Duke Clinical Research Institute.
“TIMI 50 is the largest and most rapidly enrolling trial in our 25-year history,” commented Eugene Braunwald, M.D., Chairman of the TIMI Study Group. “We are very pleased with this achievement and look forward to completing this important clinical outcome trial,” he added.
Related Categories
Corporate NewsStocks Mentioned
-0.12Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
